LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Slēgts

SektorsVeselības aprūpe

0.73 -3.95

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.72

Max

0.76

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1M

-1.2M

Pārdošana

141K

21M

Peļņas marža

-5.978

Darbinieki

330

EBITDA

1M

1.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+163.16% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

8.2M

34M

Iepriekšējā atvēršanas cena

4.68

Iepriekšējā slēgšanas cena

0.73

Ziņu noskaņojums

By Acuity

26%

74%

84 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Harvard Bioscience Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025. g. 10. dec. 21:46 UTC

Peļņas

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025. g. 10. dec. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 23:43 UTC

Tirgus saruna

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025. g. 10. dec. 23:36 UTC

Tirgus saruna

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025. g. 10. dec. 23:20 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025. g. 10. dec. 23:15 UTC

Peļņas

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025. g. 10. dec. 22:59 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025. g. 10. dec. 22:45 UTC

Tirgus saruna

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025. g. 10. dec. 22:40 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:00 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025. g. 10. dec. 21:53 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025. g. 10. dec. 21:50 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 10. dec. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 21:33 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025. g. 10. dec. 21:32 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025. g. 10. dec. 21:25 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025. g. 10. dec. 21:16 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025. g. 10. dec. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025. g. 10. dec. 21:15 UTC

Peļņas

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Salīdzinājums

Cenas izmaiņa

Harvard Bioscience Inc Prognoze

Cenas mērķis

By TipRanks

163.16% augšup

Prognoze 12 mēnešiem

Vidējais 2 USD  163.16%

Augstākais 2 USD

Zemākais 2 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harvard Bioscience Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.3 / 0.3401Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

No Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

84 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat